Page 3 - Scientific Library
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,
How sample preparation can affect your biomarker studies (II)
In a previous post, we looked at the importance of sample preparation
Montelukast improves learning & memory in aging brain
Montelukast is a marketed drug used for asthma treatment and to relieve symptoms of seasonal allergies. It is known to function as a leukotriene receptor antagonist.
Ion Channels and Cancer Immunology
Ions channels are pore-forming membrane proteins that control ion transit across the cell membrane to various stimuli. It was shown that deregulation or dysfunction of channels are clearly linked to many
CBR-5884 - a Serine biosynthesis inhibitor for cancer research
Metabolic pathways are upregulated in cancer cells to promote their growth and proliferation. The evidence pointing to the requirement of the amino acid serine in tumorigenesis is overwhelming. Serine
Two top ways to success with knock-out
In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out
Microbial K-Ras Inhibitors
Small molecules known to modulate biological activies of the K-Ras oncogene are predominantly of synthetic origin (ex. Salirasib). Nevetheless, various publications
How to activate or inhibit autophagy?
The term Autophagy was introduced by Christian de Duve during the Ciba Foundation Symposium on Lysosomes – which was held in London in February 1963. In 1974 he was honoured with
Ppc-1 small molecule: a new mitochondria uncoupling agent
Ppc-1 is a novel small molecule derived from cellular slime mould. In this post, I'd like to introduce the characteristics of this compound for your in vitro mitochondrial research.
Stauprimide inhibits c-myc transcription in cancer cells
Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization